Geographic Atrophy

Avacincaptad pegol may help preserve driving-related vision in geographic atrophy, but post hoc data did not reach statistical significance.

Biogen buys Apellis, taking over Syfovre for geographic atrophy—what it means for GA care, trial data, safety signals, and future formulations.

Three real-world GA cases reveal why early imaging-guided treatment matters, how fast vision can decline, and how to manage CNV risk with anti-VEGF.

The Opti-GAIN study from Complement Therapeutics is assessing the safety, tolerability, and preliminary efficacy in GA secondary to age-related macular degeneration (AMD) of CTx001.

Phase 2 ArMaDa data show statistically significant 31% reduction in GA lesion growth with OCU410 at 12 months, with a favorable safety profile supporting phase 3 development.

The trial, sponsored by ONL Therapeutics, aims to enroll approximately 324 patients across sites in Europe, the United States, and Canada.

The successful completion and the milestone payment “provide Galimedix with an important operational runway to proceed with plans for additional clinical development in Alzheimer’s disease and other indications."

US eye medication shortages make up a sizable share of active drug shortages and last longer, driven by manufacturing issues, weak generics and unclear causes.

Steffen Schmitz-Valckenberg, MD, discusses how optical coherence tomography-based models may enable rapid, noninvasive assessment of functional loss in GA.

From artificial intelligence and IOL innovation to biosimilars, geographic atrophy, and postoperative eye protection, Joshua Mali, MD, FASRS, shares what he believes will define ophthalmology in the year ahead.

The results of a multicenter controlled clinical trial showed that the device resulted in “a significant improvement in visual acuity (VA) from baseline to month 12.

The deal will see MeiraGTx assume development rights to ZipBio’s experimental therapies targeting the complement pathway in geographic atrophy (GA).

Imaging and biomarkers are driving earlier, more individualized GA treatment

David S. Boyer, MD, outlines changes in GA evaluation, the role of complement inhibition, monitoring for neovascular conversion, and emerging therapies.

Nanoscope's new patent enhances its innovative MCO technology, promising vision restoration for retinal degeneration with strong safety results and market potential.

The Investigational New Drug (IND) application from Complement Therapeutics for CTx001 was previously approved by the FDA in October 2025.

Knowing what’s on the market for AMD and GA aids in preserving vision.

The novel system converts light into electrical signals to stimulate retinal cells.

This approach helps distinguish diseases associated with macular atrophy.

Atrophy Advisor aids physicians in personalizing treatment for geographic atrophy in age-related macular degeneration, enhancing patient care and outcomes.

Lock in patient adherence with discussion of study results.

Results showed reduction in geographic atrophy progression and improved visual acuity.

Xelafaslatide is a small-molecule Fas inhibitor designed to protect key retinal cells, including photoreceptors, from cell death that occurs across multiple retinal diseases and conditions.

New research highlights iron dysregulation's role in dry AMD, suggesting transferrin as a promising treatment to slow disease progression.